Will Morton[email protected]Molecular ImagingChatGPT matches nuclear medicine experts on FDG-PET/CT scansModels excelled on cases with well-defined metabolic patterns, such as in typical cases of Alzheimer's disease, yet were less accurate on complex cases.April 24, 2026Practice ManagementMusculoskeletal strain affects majority of radiologistsMusculoskeletal strain represents the single largest category of workplace injury in radiology.April 23, 2026InterventionalGAE benefits may just be ‘placebo effect’Patients who received either genicular artery embolization (GAE) or a sham procedure experienced equal pain improvements.April 22, 2026Molecular ImagingFDG-PET predicts outcomes in metastatic breast cancerPatients without disease progression on FDG-PET scans 14 days after treatment had better progression-free and overall survival.April 16, 2026Molecular ImagingARRS: Do GLP-1 drugs confound FDG-PET imaging scans?No significant differences in FDG uptake were observed in the skeletal muscle, liver, blood pool, or abdominal fat following GLP-1 agonist therapy.April 13, 2026Molecular ImagingPET links brain metabolism to survival in lung cancer patientsLow brain metabolic activity was associated with increased mortality in patients with advanced NSCLC.April 9, 2026AIAI aging estimates based on chest x-rays linked to mortalityNo studies have investigated the ability of aging velocity -- the rate of change in radiographic age over time -- to predict mortality.April 3, 2026Molecular ImagingPET/CT metric improves outcome predictions in Pluvicto patientsThe inclusion of total tumor volume (TTV) produces prediction models with better discriminatory ability.March 31, 2026Radiation Oncology/TherapyASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progressionTwo cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.September 29, 2025Radiation Oncology/TherapyASTRO: Genomic test predicts benefit of hormone therapy in prostate cancerPatients with a prostate tumor subtype known as luminal B had meaningful benefits from the addition of apalutamide to secondary radiotherapy.September 29, 2025Page 1 of 51Next PageTop StoriesMolecular ImagingChatGPT matches nuclear medicine experts on FDG-PET/CT scansModels excelled on cases with well-defined metabolic patterns, such as in typical cases of Alzheimer's disease, yet were less accurate on complex cases.CTHRCT bests chest x-ray when it comes to identifying ILDEconomicsCMS, FDA align with new breakthrough medical device coverage pathwayWomens ImagingWomen's Imaging MinnieCast, Episode 7: What to know about the ACP's breast cancer screening guidanceSponsor ContentTurning Innovation into Everyday Efficiency
